AEterna Zentaris Inc (AEZS)
2.64
-0.08
(-2.94%)
USD |
NASDAQ |
Mar 24, 16:00
2.64
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 12.82M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -69.12% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.274 |
| Price to Book Value | 0.3583 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.13% |
News
Headline
Wire
Time (ET)
Globe Newswire
03/23 08:05
Yahoo
03/16 08:05
Globe Newswire
01/17 08:05
Yahoo
01/11 13:00
Globe Newswire
01/10 08:05
Globe Newswire
08/29 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/11/2023* | -- | Results | Q1 2023 | -- | -0.93 | -- | |
| 03/23/2023 | -- | Results | Q4 2022 | -2.53 | -0.93 | -172.5% | |
| 11/03/2022 | -- | Results | Q3 2022 | -0.70 | -0.68 | -2.94% | |
| 08/03/2022 | -- | Results | Q2 2022 | -0.87 | -0.68 | -27.94% | |
| 05/11/2022 | -- | Results | Q1 2022 | -0.50 | -0.02 | -2.40K% | |
| 03/29/2022 | -- | Results | Q4 2021 | -0.50 | -0.50 | 0.00% | |
| 11/04/2021 | -- | Results | Q3 2021 | -0.25 | -0.50 | 50.00% | |
| 08/04/2021 | -- | Results | Q2 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. |
| URL | https://www.zentaris.com |
| Investor Relations URL | http://ir.aezsinc.com/ |
| HQ State/Province | Ontario |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 11, 2023 (est.) |
| Last Earnings Release | Mar. 23, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
| Revenue (TTM) | 5.64M |
| Total Expenses (TTM) | 20.89M |
| Net Income (TTM) | -22.73M |
| Total Assets (Quarterly) | 56.03M |
| Total Liabilities (Quarterly) | 20.25M |
| Shareholders Equity (Quarterly) | 35.78M |
| Cash from Operations (TTM) | -13.68M |
| Cash from Investing (TTM) | -0.012M |
| Cash from Financing (TTM) | -0.118M |
Ratings
Profile
Edit
| AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. |
| URL | https://www.zentaris.com |
| Investor Relations URL | http://ir.aezsinc.com/ |
| HQ State/Province | Ontario |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 11, 2023 (est.) |
| Last Earnings Release | Mar. 23, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| AEZS Tweets |